Charlotte Robinson

DocwireNews

Makana Therapeutics announced the discovery of a fourth gene in pigs that, when inactivated, could significantly reduce the risk of organ rejection in a human transplant recipient.Makana researchers previously discovered three key xenoantigens that pigs have on the surface of their cells and &ldquo;knocked out&rdquo; the genes in the pig that cause the cells to express these xenoantigens. The company&rsquo;s Triple Knockout Pig, or TKO, is the current foundational genetics used across the field and is deficient in those three genes.During recent discovery efforts, every human sample Makana analyzed contained antibodies to the antigen eliminated by Makana&rsquo;s fourth genetic target. Specifics of Makana&rsquo;s research will be published in the coming weeks.Mark Platt, the company&rsquo;s chief executive officer, stated that pigs incorporating this knockout were produced last year as part of a research collaboration with the University of Miami. He said that Makana plans to launch a preclinical study in 2025 and hopes to conduct a first-in-human clinical trial in kidney xenotransplantation in early 2026 upon approval by the US Food and Drug Administration.

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Latest News

Makana Hails Its Latest Discovery as a Breakthrough in Pig-to-Human Transplantation

Kidney Transplantation

Makana Therapeutics has discovered a fourth pig gene that, when inactivated, could greatly reduce organ rejection risk. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe